METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Metformin Hydrochloride; Saxagliptin Hydrochloride, and what generic alternatives are available?
Metformin Hydrochloride; Saxagliptin Hydrochloride is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.
The generic ingredient in METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metformin Hydrochloride; Saxagliptin Hydrochloride
A generic version of METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE was approved as metformin hydrochloride; saxagliptin hydrochloride by DR REDDYS LABS SA on August 9th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE?
- What are the global sales for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE?
- What is Average Wholesale Price for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE?
Summary for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Recent Clinical Trials for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sabyasachi Sen | Phase 4 |
| Shenzhen Sixth People's Hospital | Phase 4 |
| Dongguan Kanghua Hospital | Phase 4 |
See all METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE clinical trials
Pharmacology for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
| Drug Class | Biguanide Dipeptidyl Peptidase 4 Inhibitor |
| Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Paragraph IV (Patent) Challenges for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| KOMBIGLYZE XR | Extended-release Tablets | metformin hydrochloride; saxagliptin hydrochloride | 5 mg/500 mg 2.5 mg/1000 mg 5 mg/1000 mg | 200678 | 3 | 2013-07-31 |
US Patents and Regulatory Information for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 207678-001 | Aug 9, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Dr Reddys Labs Sa | METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 207678-002 | Aug 9, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Dr Reddys Labs Sa | METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 207678-003 | Aug 9, 2023 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
